ELI LILLY AND COMPANY announced that Maura Dickler, MD, a breast cancer clinical researcher at the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSK), will join Lilly Oncology as Vice President of Late Phase Development in early May 2018.Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
Dr. Dickler is currently Section Head of the Endocrine Therapy Clinical Research Program at MSK. She concurrently serves as Associate Member of Breast Medicine Service in the Department of Medicine at MSK and is Associate Professor of Medicine at Weill Cornell Medical College.
Dr. Dickler’s research has focused on developing new therapeutic strategies for the treatment of women with hormone receptor–positive breast cancer and has led clinical trials investigating therapeutic agents targeting various signaling pathways, including the epidermal growth factor receptor, HER2, vascular endothelial growth factor receptor, phosphoinositide 3-kinase, and the estrogen receptor pathway. She has also investigated cyclin-dependent kinase 4/6 inhibitors. ■